 Microsomes, Liver
"Microsomes, Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough.
| Descriptor ID |
D008862
|
| MeSH Number(s) |
A11.284.835.540.541
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Microsomes, Liver".
Below are MeSH descriptors whose meaning is more specific than "Microsomes, Liver".
This graph shows the total number of publications written about "Microsomes, Liver" by people in UAMS Profiles by year, and whether "Microsomes, Liver" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 1 | 2 | | 2021 | 1 | 2 | 3 | | 2020 | 2 | 4 | 6 | | 2019 | 2 | 3 | 5 | | 2018 | 2 | 3 | 5 | | 2017 | 1 | 1 | 2 | | 2016 | 0 | 2 | 2 | | 2015 | 1 | 5 | 6 | | 2014 | 4 | 3 | 7 | | 2013 | 2 | 6 | 8 | | 2012 | 1 | 4 | 5 | | 2011 | 3 | 4 | 7 | | 2010 | 0 | 4 | 4 | | 2009 | 1 | 1 | 2 | | 2008 | 2 | 6 | 8 | | 2007 | 1 | 6 | 7 | | 2006 | 1 | 4 | 5 | | 2005 | 1 | 5 | 6 | | 2004 | 3 | 3 | 6 | | 2003 | 0 | 5 | 5 | | 2002 | 1 | 2 | 3 | | 2001 | 0 | 3 | 3 | | 2000 | 1 | 3 | 4 | | 1999 | 2 | 1 | 3 | | 1998 | 1 | 0 | 1 | | 1994 | 1 | 1 | 2 | | 1993 | 0 | 1 | 1 | | 1992 | 4 | 4 | 8 | | 1991 | 3 | 1 | 4 | | 1990 | 0 | 1 | 1 | | 1989 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Microsomes, Liver" by people in Profiles over the past ten years.
-
Laizure SC, Chen F, Farrar JE, Ali D, Yang B, Parker RB. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation. Drug Metab Pharmacokinet. 2022 Dec; 47:100479.
-
Jackson KD, Argikar UA, Cho S, Crouch RD, Driscoll JP, Heck CJS, King L, Maw HH, Miller GP, Seneviratne HK, Wang S, Wei C, Zhang D, Khojasteh SC. Bioactivation and reactivity research advances - 2021 year in review. Drug Metab Rev. 2022 08; 54(3):246-281.
-
Schleiff MA, Crosby S, Blue M, Schleiff BM, Boysen G, Miller GP. CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochem Pharmacol. 2021 12; 194:114824.
-
Cui H, Carlson AS, Schleiff MA, Divakaran A, Johnson JA, Buchholz CR, Zahid H, Vail NR, Shi K, Aihara H, Harki DA, Miller GP, Topczewski JJ, Pomerantz WCK. 4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity. J Med Chem. 2021 07 22; 64(14):10497-10511.
-
Schleiff MA, Payakachat S, Schleiff BM, Swamidass SJ, Boysen G, Miller GP. Impacts of diphenylamine NSAID halogenation on bioactivation risks. Toxicology. 2021 06 30; 458:152832.
-
Barnette DA, Schleiff MA, Datta A, Flynn N, Swamidass SJ, Miller GP. Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam. Toxicol Lett. 2021 Mar 01; 338:10-20.
-
Schleiff MA, Flynn NR, Payakachat S, Schleiff BM, Pinson AO, Province DW, Swamidass SJ, Boysen G, Miller GP. Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics. Drug Metab Dispos. 2021 02; 49(2):133-141.
-
Pinson AO, Pouncey DL, Schleiff MA, Fantegrossi WE, Prather PL, Radominska-Pandya A, Boysen G, Miller GP. Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules. 2020 Oct 20; 25(20).
-
Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacol Biochem Behav. 2020 08; 195:172949.
-
Barnette DA, Schleiff MA, Osborn LR, Flynn N, Matlock M, Swamidass SJ, Miller GP. Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam. Toxicology. 2020 07; 440:152478.
-
Liu X, Poddar S, Song L, Hendrickson H, Zhang X, Yuan Y, Zhou D, Zheng G. Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine-Substituted d-Tocotrienol Derivative. ChemMedChem. 2020 03 18; 15(6):506-516.
-
Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJ, Ramanathan S, Sharma A, Le?n F, Hiranita T, Avery BA, McMahon LR, McCurdy CR. Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. J Med Chem. 2020 01 09; 63(1):433-439.
-
Reed L, Jarvis IWH, Phillips DH, Arlt VM. Deletion of cytochrome P450 oxidoreductase enhances metabolism and DNA adduct formation of benzo[a]pyrene in Hepa1c1c7 cells. Mutagenesis. 2019 12 19; 34(5-6):413-420.
-
Barnette DA, Davis MA, Flynn N, Pidugu AS, Swamidass SJ, Miller GP. Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation. Biochem Pharmacol. 2019 12; 170:113661.
-
Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica. 2019 Dec; 49(12):1388-1395.
-
Reed L, Indra R, Mrizova I, Moserova M, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM. Application of hepatic cytochrome b5/P450 reductase null (HBRN) mice to study the role of cytochrome b5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine. Toxicol Appl Pharmacol. 2019 03 01; 366:64-74.
-
Wilson CD, Tai S, Ewing L, Crane J, Lockhart T, Fujiwara R, Radominska-Pandya A, Fantegrossi WE. Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. J Pharmacol Exp Ther. 2019 02; 368(2):146-156.
-
Kim SY, Jones DR, Kang JY, Yun CH, Miller GP. Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin. Xenobiotica. 2019 Apr; 49(4):397-403.
-
Dang NL, Hughes TB, Miller GP, Swamidass SJ. Computationally Assessing the Bioactivation of Drugs by N-Dealkylation. Chem Res Toxicol. 2018 02 19; 31(2):68-80.
-
Reed L, Mrizova I, Barta F, Indra R, Moserova M, Kopka K, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM. Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice. Arch Toxicol. 2018 Apr; 92(4):1625-1638.
-
Williams DK, Markwalder JA, Balog AJ, Chen B, Chen L, Donnell J, Haque L, Hart AC, Mandal SK, Nation A, Shan W, Vite GD, Covello K, Hunt JT, Jure-Kunkel MN, Seitz SP. Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Bioorg Med Chem Lett. 2018 02 15; 28(4):732-736.
-
Fujiwara R, Yoda E, Tukey RH. Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans. Drug Metab Pharmacokinet. 2018 Feb; 33(1):9-16.
-
Koyama M, Shirahata T, Hirashima R, Kobayashi Y, Itoh T, Fujiwara R. Inhibition of UDP-glucuronosyltransferase (UGT)-mediated glycyrrhetinic acid 3-O-glucuronidation by polyphenols and triterpenoids. Drug Metab Pharmacokinet. 2017 Aug; 32(4):218-223.
-
Haarhoff ZE, Kramer MA, Zvyaga TA, Zhang J, Bhutani P, Subramanian M, Rodrigues AD. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human. Xenobiotica. 2017 Jun; 47(6):470-478.
-
Hines RN, Simpson PM, McCarver DG. Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny. Drug Metab Dispos. 2016 07; 44(7):959-66.
-
Hartman JH, Letzig LG, Roberts DW, James LP, Fifer EK, Miller GP. Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures. Biochem Pharmacol. 2015 Oct 01; 97(3):341-9.
-
Krais AM, Speksnijder EN, Melis JP, Indra R, Moserova M, Godschalk RW, van Schooten FJ, Seidel A, Kopka K, Schmeiser HH, Stiborova M, Phillips DH, Luijten M, Arlt VM. The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice. Arch Toxicol. 2016 Apr; 90(4):839-51.
-
Takagi M, Sakamoto M, Itoh T, Fujiwara R. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. Drug Metab Pharmacokinet. 2015 Aug; 30(4):288-94.
-
Kutsuno Y, Hirashima R, Sakamoto M, Ushikubo H, Michimae H, Itoh T, Tukey RH, Fujiwara R. Expression of UDP-Glucuronosyltransferase 1 (UGT1) and Glucuronidation Activity toward Endogenous Substances in Humanized UGT1 Mouse Brain. Drug Metab Dispos. 2015 Jul; 43(7):1071-6.
-
Oda S, Fujiwara R, Kutsuno Y, Fukami T, Itoh T, Yokoi T, Nakajima M. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. Drug Metab Dispos. 2015 Jun; 43(6):812-8.
-
Asakura M, Fujii H, Atsuda K, Itoh T, Fujiwara R. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver. Drug Metab Dispos. 2015 Apr; 43(4):477-84.
-
Pugh CP, Pouncey DL, Hartman JH, Nshimiyimana R, Desrochers LP, Goodwin TE, Boysen G, Miller GP. Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites. Arch Biochem Biophys. 2014 Dec 15; 564:244-53.
-
Fujiwara R, Sumida K, Kutsuno Y, Sakamoto M, Itoh T. UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin. Drug Metab Pharmacokinet. 2015 Feb; 30(1):82-8.
-
Asakura M, Nakano M, Hayashida K, Fujii H, Nakajima M, Atsuda K, Itoh T, Fujiwara R. Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin. Drug Metab Pharmacokinet. 2014; 29(6):463-9.
-
Greer AK, Dates CR, Starlard-Davenport A, Edavana VK, Bratton SM, Dhakal IB, Finel M, Kadlubar SA, Radominska-Pandya A. A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives. Drug Metab Dispos. 2014 Sep; 42(9):1392-400.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|